LVGO Livongo Health

Livongo Provides New Diabetes Management Solution to New Jersey State and School Health Plan Members

Livongo Provides New Diabetes Management Solution to New Jersey State and School Health Plan Members

In partnership with Horizon Blue Cross Blue Shield of New Jersey and the State of New Jersey, Livongo for Diabetes is now available to over 460,000 people; bringing digital health to the forefront of Member health benefits

MOUNTAIN VIEW, Calif., Jan. 21, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced that Livongo’s Applied Health Signals platform will be available to New Jersey State and School Employee Health Plan Members. Livongo, in partnership with Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ), will make the Livongo for Diabetes solution available to over 460,000 public employees and their dependents. 

“As the prevalence and cost of chronic conditions continues to rise, we are excited to be able to offer these new tools and services to make it easier for our members to manage their health,” said Christin Deacon, Assistant Director for the State of New Jersey, Division of Pensions and Benefits. “Working within the partnership between Livongo and Horizon Blue Cross Blue Shield of New Jersey, we are now able to bring the industry leading Livongo benefit to the thousands of New Jersey State and School Health Plan Members living with diabetes.”

Livongo makes it easier for Members to manage their health by providing a connected ecosystem that includes cellular-connected devices and integration with continuous glucose monitors, 24/7 access to health coaches, and real-time health insights delivered through Health Nudges. The Applied Health Signals platform leverages data science to understand people’s unique health needs and then provide clinically-based guidance to drive positive behavior change. The Livongo for Diabetes solution leads to higher Member satisfaction1, improved clinical outcomes2, and lower overall healthcare spending3.

“Livongo is in a unique position to provide our Applied Health Signals solutions to state employees, improving their overall experience, while reducing costs related to chronic condition management,” said Livongo Chief Executive Officer Zane Burke. “Our partnership with the State of New Jersey and Horizon BCBSNJ is another example of the significant progress we are making across broader markets, including state and local governments.”

Livongo currently has more than 770 clients, including more than 20 percent of Fortune 500 companies, four of the top seven health plans, and two of the nation’s largest pharmacy benefit managers as partners. A 2019 study conducted in collaboration with Eli Lilly and Company demonstrated that 94 percent of Livongo for Diabetes program Members who completed a program survey achieved improved Diabetes Empowerment Scale – Short Form (DES-SF) or Diabetes Distress Scale 2 (DDS2) in year one of the Livongo for Diabetes Program; effectively improving confidence in diabetes self-management while decreasing burnout related to diabetes management.

Livongo expects, after having been selected by the State of New Jersey in the fourth quarter of 2019, that this agreement will make approximately 29,000 people eligible for the Livongo for Diabetes program and add approximately 5,000 Members in 2020 as anticipated in the plan for this current year.

About Livongo

Livongo offers a platform to care for the whole person and empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including hypertension, weight management, diabetes prevention, and behavioral health. Livongo pioneered the category of Applied Health Signals to offer Members clinically-based insights that make it easier to stay healthy. Livongo’s team of data scientists aggregate and interpret substantial amounts of health data and information to create actionable, personalized and timely health signals delivered to Livongo Members exactly when and where they need them. The Livongo approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions. For more information, visit: or engage with Livongo on or .

Media Contact:

John Hallock

 

617-615-7712

Investor Contact:

Alex Hughes



650-413-9528

_________________________________

1
November 2018 Business Report

2 JENNIFER BOLLYKY, WEI LU, JENNIFER SCHNEIDER

Diabetes Jul 2018, 67 (Supplement 1) 406-P; DOI: 10.2337/db18-406-P

3 Christopher M. Whaley, Jennifer B. Bollyky, Wei Lu, Stefanie Painter, Jennifer Schneider, Zhenxiang Zhao, Xuanyao He, Jennal Johnson & Eric S. Meadows (2019) Reduced medical spending associated with increased use of a remote diabetes management program and lower mean blood glucose values, Journal of Medical Economics, 22:9, 869-877, DOI: 

 

EN
21/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Livongo Health

 PRESS RELEASE

Livongo Reports Third Quarter 2020 Financial Results

Livongo Reports Third Quarter 2020 Financial Results Third quarter total revenue of $106.1 million, up 126% year-over-yearOver 442,000 enrolled Livongo for Diabetes Members, up 113% year-over-year MOUNTAIN VIEW, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc. (NASDAQ: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced financial results for its third quarter ended September 30, 2020. “Livongo delivered another quarter of greater than 100% revenue growth, driven by stronger than...

 PRESS RELEASE

Livongo to Release Results for the Third Quarter of Fiscal Year 2020

Livongo to Release Results for the Third Quarter of Fiscal Year 2020 MOUNTAIN VIEW, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO) today announced it will release its financial results for its third quarter of fiscal year 2020 on October 28, 2020, after close of the U.S. stock market. Given the pending transaction with Teladoc Health, Livongo is not hosting a conference call in conjunction with its third quarter of 2020 earnings release. About Livongo Livongo empowers people with chronic conditions to live better and healthier lives, beginning with diabet...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2020 09 08

BHC currently trades well below corporate averages relative to Uniform earnings, with a 9.1x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to fall from 45% in 2019 to 20% in 2024, accompanied by 2% Uniform asset growth going forward. However, analysts have bullish expectations, projecting Uniform ROA to expand to 51% by 2021, accompanied by 3% Uniform asset shrinkage. Furthermore, management is confident about the eye health spinoff, script recovery, and Pro...

 PRESS RELEASE

Livongo to Present at Upcoming Investor Conferences

Livongo to Present at Upcoming Investor Conferences MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced that executives from the Company, together with executives from Teladoc Health, will be presenting at the following upcoming investor conferences and discussing their pending merger: Wells Fargo Securities Healthcare Conference on Thursday, September 10 at 8:00 a.m. Eastern TimeMorgan Stanley 18th Annual Glo...

Valens Research
  • Valens Research

LVGO - Embedded Expectations Analysis - 2020 09 02

Livongo Health, Inc. (LVGO:USA) currently trades above historical averages relative to UAFRS-based (Uniform) earnings, with a 166.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may be concerned about running at a net loss, Teladoc merger benefits, and the usefulness of their diabetes studies Specifically, management may lack confidence in their ability to generate a net profit, sustain Adjusted EBITDA growth, and continue generating contract wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch